Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai, Guangdong, China, 519000, Zhuhai, Guangdong, China
Contact: Study coordinator (Ming-Yuan Chen, MD, PhD) · chmingy@mail.sysu.edu.cn · +86-13903052650

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Dublin, United States · Fremont, United States

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chongqing, China · Fuzhou, China

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Guangzhou, China

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Zhuhai, China